Synthetic dimeric-drug phospholipid: a versatile liposomal platform for cancer therapy

Chem Commun (Camb). 2020 Jul 14;56(55):7621-7624. doi: 10.1039/d0cc03589k. Epub 2020 Jun 9.

Abstract

An amphiphilic dimeric-podophyllotoxin (PODO) phospholipid was synthesized to assemble into liposomes as a combination of prodrug and nanocarrier. The results have demonstrated that the cell membrane-like delivery system possessed an improved cellular uptake and favorable antitumor efficacy with reduced side-effects. This strategy provides a new effective platform in drug delivery for cancer chemotherapy.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Drug Carriers / chemical synthesis
  • Drug Carriers / chemistry
  • Female
  • Humans
  • Liposomes / chemical synthesis
  • Liposomes / chemistry
  • Liposomes / therapeutic use*
  • Mice, Inbred BALB C
  • Neoplasms / drug therapy*
  • Phosphatidylcholines / chemical synthesis
  • Phosphatidylcholines / chemistry
  • Phosphatidylcholines / therapeutic use*
  • Podophyllotoxin / analogs & derivatives*
  • Podophyllotoxin / chemical synthesis
  • Podophyllotoxin / therapeutic use*
  • Prodrugs / chemical synthesis
  • Prodrugs / chemistry
  • Prodrugs / therapeutic use
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Liposomes
  • Phosphatidylcholines
  • Prodrugs
  • Podophyllotoxin